Intravesical Bacillus Calmette-Guerin (BCG) is an effective immunotherapy for non-muscle invasive bladder cancer (NMIBC). However, recurrence and progression remain frequent warranting deeper insights into its mechanism.
Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC). To determine this, we undertook a cross-sectional survey covering 10% of the English population.
To adapt the management of prostate malignancy in response to the COVID-19 pandemic. In according to the recommendations of the European Association of Urology, we have developed practical additional document on the treatment of prostate cancer.
(UroToday.com) The TITAN phase III clinical trial evaluated apalutamide or placebo added to ADT in patients with men with metastatic castration sensitive prostate cancer (mCSPC). Patients with high- and low-volume disease, prior docetaxel, prior treatment for localized disease, and prior ADT (≤ 6 months) were eligible for the trial. At the first interim analysis, with 22.7 months […]
(UroToday.com) The largest United States cancer health disparity exists in prostate cancer, with African American men having:
(UroToday.com) Cisplatin-based chemotherapy is the standard of care in first-line for metastatic urothelial carcinoma and is associated with an overall survival benefit. However, approximately half of patients with locally advanced or metastatic urothelial carcinoma in the US are cisplatin-ineligible. Cisplatin-ineligible, platinum-naive patients with locally advanced or metastatic urothelial carcinoma who progress on or after PD-1/L1 inhibitors have […]
(UroToday.com) Platinum-based chemotherapy, sequenced with programmed cell death protein-1/programmed death-ligand 1 (PD-1/L1) inhibitors, is the standard of care for patients with advanced urothelial carcinoma. Platinum-based chemotherapy used in the first-line is associated with response rates of 36-64%, but intrinsic and acquired resistance occurs. PD-1/L1 inhibitors are used in the first-line, first-line maintenance, and in platinum-refractory disease, with […]
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Anne Schuckman discussing which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy. Dr. Shuckman notes that more than 70% of all newly diagnosed bladder cancers are […]
(UroToday.com) Tucatinib is a highly selective HER2-directed tyrosine-kinase inhibitor recently approved for HER2 overexpressed/amplified (HER2+) metastatic breast cancer and is being developed as a novel therapy for patients with metastatic colorectal cancer, gastric cancer, and other gastrointestinal tumors. In xenograft models of HER2+ and HER2-mutated tumors, dual targeting of HER2 with tucatinib and trastuzumab showed superior […]
(UroToday.com) Though clinical outcomes for advanced germ cell tumors have been significantly improved with the utilization of cisplatin-based chemotherapy regimens, approximately 400 patients a year die from relapsed or refractory germ cell tumors. To further explore the genetic properties of cisplatin refractory or relapsed germ cell tumors, 52 tumors from a single institution were profiled using […]
